This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of -15.79% and 80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 9.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 21.05% and 58.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
by Zacks Equity Research
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of -7.81% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 36.17% and 37.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -42.86% and 6.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 163.83% and 37.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 18.75% and 9.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of -521.05% and 56.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -16.95% and 58.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 25.49% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of -2.42% and 3.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 13.85% and 19.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 7.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 1.59% and 9.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals, Inc. (CASI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 40% and 0.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals, Inc. (CASI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CASI Pharma (CASI) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
CASI Pharma (CASI) has been struggling lately, but the selling pressure may be coming to an end soon.
CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 44.44% and 16.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CASI Pharmaceuticals, Inc. (CASI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.